Payloads: IL-12, IL-15/IL-15Rα
Enhanced viral replication in CEA+ tumors
Virogin is dedicated to bringing next-generation immuno-oncolytic therapeutics to the clinic through our robust pipeline.
Payloads: IL-12, IL-15/IL-15Rα
Enhanced viral replication in CEA+ tumors
China
Payloads: IL-12, IL-15/IL-15Rα
Enhanced viral replication in CEA+ tumors
United States
Payloads: IL-12, IL-15 / IL-15Rα, PD-L1 blocking peptide
China
Payloads: IL-12, IL-15 / IL-15Rα, PD-L1 blocking peptide
China
Payloads: IL-12, IL-15 / IL-15Rα, PD-L1 blocking peptide
China
Payloads: IL-12, IL-15 / IL-15Rα, PD-L1 blocking peptide
China
Payloads: IL-12, IL-15 / IL-15Rα, PD-L1 blocking peptide
Australia
Payloads: IL-12, IL-15 / IL-15Rα, PD-L1 blocking peptide
United States
*VG161 to be developed for the Greater China market in partnership with CNBG, a Sinopharm Subsidiary (Virogin Biotech retains worldwide rights excluding Greater China)
IND = Investigational New Drug; TTDR = Transcription & translation dual regulation; ICP = Infected cell protein; IL = Interleukin; CEA = Carcinoembryonic antigen
Expanded access to any of Virogin’s investigational products can only be requested by a licensed physician who is willing to oversee the patient’s treatment, files the necessary paperwork with FDA and IRB, and is responsible for patient care and reporting.
Submit a request below:
